Lonza and Genetix extended their commercial manufacturing agreement to expand production of ZYNTEGLO™ at Lonza’s Houston cell and gene therapy site. The renewed deal secures additional capacity to meet rising patient demand for the only FDA‑approved gene therapy for transfusion‑dependent beta‑thalassemia and includes provisions to scale for future Genetix programs. Lonza’s Daniel Palmacci emphasized the company’s specialized modality capabilities, while Genetix CTO Brian Riley noted growing patient demand and the need for reliable commercial supply. The agreement continues a collaboration that began in 2013 and supported ZYNTEGLO’s 2022 approval. Practical note: commercial manufacture of ex vivo gene therapies requires dedicated facilities, quality systems and supply‑chain integration; long‑term manufacturing partnerships are a common de‑risking strategy for cell and gene developers.